Carbon 11 dimethyl diphenyl ammonium - Synektik
Alternative Names: [11C]-DMDPA; C11 DMDPALatest Information Update: 28 Aug 2024
At a glance
- Originator Hadassah Medical Organization
- Developer Hadassah Medical Organization; Synektik S.A
- Class Imaging agents; Radiopharmaceutical diagnostics; Vascular disorder therapies
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Coronary artery disease
Most Recent Events
- 28 Aug 2024 Synektik SA completes a phase III trial in Coronary artery disease (Diagnosis) in Poland (IV), prior to August 2024 (EudraCT2021-002557-29)
- 25 Oct 2021 Phase-III clinical trials in Coronary artery disease (Diagnosis) in Poland (IV) (EudraCT2021-002557-29)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis, In volunteers) in Israel (IV, Injection)